Barclays’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3
| Closed | -$1 | – | 4819 |
|
|
2023
Q2 | $1 | Hold |
3
| – | – | ﹤0.01% | 4494 |
|
|
2023
Q1 | $2 | Hold |
3
| – | – | ﹤0.01% | 5051 |
|
|
2022
Q4 | $2 | Hold |
3
| – | – | ﹤0.01% | 5254 |
|
|
2022
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 5262 |
|
|
2022
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 5401 |
|
|
2022
Q1 | $0 | Buy |
+3
| New | +$17 | ﹤0.01% | 5780 |
|
|
2019
Q4 | – | Sell |
-3
| Closed | – | – | 6975 |
|
|
2019
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7273 |
|
|
2019
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 7406 |
|
|
2019
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 7440 |
|
|
2018
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 7486 |
|
|
2018
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7493 |
|
|
2018
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 7400 |
|
|
2018
Q1 | $1K | Hold |
3
| – | – | ﹤0.01% | 6985 |
|
|
2017
Q4 | $1K | Hold |
3
| – | – | ﹤0.01% | 6878 |
|
|
2017
Q3 | $1K | Hold |
3
| – | – | ﹤0.01% | 6787 |
|
|
2017
Q2 | $2K | Hold |
3
| – | – | ﹤0.01% | 6457 |
|
|
2017
Q1 | $2K | Hold |
3
| – | – | ﹤0.01% | 6510 |
|
|
2016
Q4 | $1K | Hold |
3
| – | – | ﹤0.01% | 6516 |
|
|
2016
Q3 | $1K | Hold |
3
| – | – | ﹤0.01% | 6482 |
|
|
2016
Q2 | $1K | Hold |
3
| – | – | ﹤0.01% | 6193 |
|
|
2016
Q1 | $1K | Hold |
3
| – | – | ﹤0.01% | 6034 |
|
|
2015
Q4 | $1K | Buy |
+3
| New | +$2.17K | ﹤0.01% | 5877 |
|
|
2013
Q4 | – | Sell |
-4
| Closed | -$12K | – | 7732 |
|
|
2013
Q3 | $12K | Buy |
+4
| New | +$6.85K | ﹤0.01% | 6732 |
|
Barclays's VYNT Position: Q3 2023 in Review
Barclays sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2023, closing a stake of 3 shares — an estimated $1 sold.
Barclays first reported a position in VYNT in Q3 2013 and held it in 23 quarters. The position peaked at $12K in Q3 2013. 0 funds tracked by Wall St. Rank hold VYNT as of Q3 2023.
- Barclays reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Barclays sold 3 Vyant Bio, Inc. Common Stock shares in Q3 2023, an estimated $1.
- Barclays first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 23 quarters.
- Barclays's Vyant Bio, Inc. Common Stock position peaked at $12K in Q3 2013.
- 0 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2023.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.